Chronic GVHD characteristics at enrollment (n = 328)
| Characteristic . | N (%) . |
|---|---|
| Sites involved | |
| Skin | 206 (63) |
| Eyes | 144 (44) |
| Mouth | 209 (64) |
| Liver (1 unknown) | 188 (57) |
| Gastrointestinal | 120 (37) |
| Lung symptoms or abnormal lung function | 158 (48) |
| Bronchiolitis obliterans or cryptogenic organizing pneumonia | 16 (5) |
| Joints | 80 (24) |
| Genital tract (26 unknown) | 30 (10) |
| Number of sites involved | |
| 1 or 2 | 86 (26) |
| 3 | 94 (29) |
| ≥4 | 148 (45) |
| NIH global severity | |
| Mild | 30 (9) |
| Moderate | 160 (49) |
| Severe | 138 (42) |
| Subcategory of GVHD | |
| Classic | 37 (11) |
| Overlap | 291 (89) |
| Karnofsky score | |
| 80-100 | 222 (68) |
| <80 | 106 (32) |
| Platelet count* | |
| <100 000 per µL | 60 (18) |
| ≥100 000 per µL | 267 (82) |
| Serum total bilirubin | |
| >2 mg/dL | 22 (7) |
| ≤2 mg/dL | 306 (93) |
| Progressive onset* | |
| No | 238 (73) |
| Yes | 89 (27) |
| Prior grade II–IV acute GVHD | |
| No | 146 (45) |
| Yes | 182 (55) |
| Onset during treatment with prednisone | |
| None | 227 (69) |
| <0.5 mg/kg/d | 65 (20) |
| ≥0.5 and <1.0 mg/kg/d | 22 (7) |
| ≥1.0 mg/kg/d | 13 (4) |
| Dose unknown | 1 (< 1) |
| Initial treatment of chronic GVHD | |
| Prednisone ± calcineurin inhibitor alone | 189 (58) |
| Prednisone ± calcineurin inhibitor + other agents | 95 (29) |
| Mycophenolate mofetil included | 32 (10) |
| Sirolimus included | 44 (13) |
| Other agents included | 28 (9) |
| No prednisone | 44 (13) |
| Calcineurin inhibitor included | 34 (10) |
| Mycophenolate mofetil included | 9 (3) |
| Sirolimus included | 5 (2) |
| Other agents included | 7 (2) |
| Prednisone dose for initial treatment | |
| None | 44 (13) |
| <0.5 mg/kg/d | 68 (21) |
| ≥0.5 and <1.0 mg/kg/d | 107 (33) |
| 1.0 mg/kg/d | 55 (17) |
| >1.0 mg/kg/d | 36 (11) |
| Dose unknown | 18 (5) |
| Number of agents for initial treatment | |
| 1 | 85 (26) |
| 2 | 187 (57) |
| ≥3 | 56 (17) |
| Characteristic . | N (%) . |
|---|---|
| Sites involved | |
| Skin | 206 (63) |
| Eyes | 144 (44) |
| Mouth | 209 (64) |
| Liver (1 unknown) | 188 (57) |
| Gastrointestinal | 120 (37) |
| Lung symptoms or abnormal lung function | 158 (48) |
| Bronchiolitis obliterans or cryptogenic organizing pneumonia | 16 (5) |
| Joints | 80 (24) |
| Genital tract (26 unknown) | 30 (10) |
| Number of sites involved | |
| 1 or 2 | 86 (26) |
| 3 | 94 (29) |
| ≥4 | 148 (45) |
| NIH global severity | |
| Mild | 30 (9) |
| Moderate | 160 (49) |
| Severe | 138 (42) |
| Subcategory of GVHD | |
| Classic | 37 (11) |
| Overlap | 291 (89) |
| Karnofsky score | |
| 80-100 | 222 (68) |
| <80 | 106 (32) |
| Platelet count* | |
| <100 000 per µL | 60 (18) |
| ≥100 000 per µL | 267 (82) |
| Serum total bilirubin | |
| >2 mg/dL | 22 (7) |
| ≤2 mg/dL | 306 (93) |
| Progressive onset* | |
| No | 238 (73) |
| Yes | 89 (27) |
| Prior grade II–IV acute GVHD | |
| No | 146 (45) |
| Yes | 182 (55) |
| Onset during treatment with prednisone | |
| None | 227 (69) |
| <0.5 mg/kg/d | 65 (20) |
| ≥0.5 and <1.0 mg/kg/d | 22 (7) |
| ≥1.0 mg/kg/d | 13 (4) |
| Dose unknown | 1 (< 1) |
| Initial treatment of chronic GVHD | |
| Prednisone ± calcineurin inhibitor alone | 189 (58) |
| Prednisone ± calcineurin inhibitor + other agents | 95 (29) |
| Mycophenolate mofetil included | 32 (10) |
| Sirolimus included | 44 (13) |
| Other agents included | 28 (9) |
| No prednisone | 44 (13) |
| Calcineurin inhibitor included | 34 (10) |
| Mycophenolate mofetil included | 9 (3) |
| Sirolimus included | 5 (2) |
| Other agents included | 7 (2) |
| Prednisone dose for initial treatment | |
| None | 44 (13) |
| <0.5 mg/kg/d | 68 (21) |
| ≥0.5 and <1.0 mg/kg/d | 107 (33) |
| 1.0 mg/kg/d | 55 (17) |
| >1.0 mg/kg/d | 36 (11) |
| Dose unknown | 18 (5) |
| Number of agents for initial treatment | |
| 1 | 85 (26) |
| 2 | 187 (57) |
| ≥3 | 56 (17) |
One is unknown.